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Abstract
Background: Liver cancer is the second leading cause of cancer death in men worldwide. Hepatocellular carcinoma
usually develops in the setting of cirrhosis or chronic inflammation. Major risk factors for developing hepatocellular
carcinoma are chronic hepatitis B or C virus infection, alcoholic cirrhosis, and nonalcoholic fatty liver disease. The most
frequent locations for hepatocellular carcinoma to metastasize are the lungs, portal vein, bones, and regional
lymph nodes.
Case presentation: A 41-year-old Sri Lankan man presented with progressive abdominal distension and on
examination was found to have a palpable irregular mass in the left lobe of his liver with moderate ascites. His
ascitic fluid was an exudate without malignant cells. An ultrasound scan and contrast-enhanced computed
tomography of his abdomen showed a large contrast-enhancing lesion in the left lobe of his liver without
features of cirrhosis. Laparoscopic assessment revealed peritoneal and omental deposits. Histology of the biopsies
taken from the liver lesion, omental deposits, and peritoneal deposits supported a diagnosis of hepatocellular
carcinoma. His liver biochemistry was normal and hepatitis serology was negative. He is abstinent from alcohol
and did not have metabolic syndrome.
Conclusions: It is rare for a young patient to develop hepatocellular carcinoma with a normal liver without chronic
hepatitis B or C infection, or any other risk factors. Intraperitoneal metastasis of non-ruptured hepatocellular carcinoma
is also very rare. Here we report a rare case of a 41-year-old man with a large hepatocellular carcinoma in a
non-cirrhotic liver without chronic hepatitis who presented with peritoneal and omental metastasis.
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Background
Liver cancer is commoner in men than in women. In
men, it is the second most leading cause of cancer death
in less developed countries; in more developed coun-
tries, it is the sixth leading cause of cancer deaths among
men [1]. The major risk factors for developing hepato-
cellular carcinoma (HCC) are hepatitis B viral infection,
chronic hepatitis C virus (HCV) infection, alcoholic cir-
rhosis, hereditary hemochromatosis, nonalcoholic fatty
liver disease, environmental toxins (aflatoxin and con-
taminated drinking water), and cirrhosis of almost any
cause [2]. HCC in a non-cirrhotic liver without any of
the risk factors is rare [3]. Intraperitoneal metastasis of
a non-ruptured HCC is also rare [4]. Here we describe
a 41-year-old man presenting with a large HCC in a
non-cirrhotic liver with peritoneal and omental metas-
tasis and moderate ascites. He was tested and was nega-
tive for hepatitis serology and other risk factors for
cirrhosis. He refused any intervention and wished to be
managed conservatively.
Case presentation
A 41-year-old Sri Lankan man presented to our unit
with progressive abdominal distension and discomfort
for 3 months. He also noticed loss of appetite and loss
of weight for the same period of time. There was no his-
tory of sudden epigastric or right hypochondrial pain,
hematemesis, melena, per rectal bleeding, or altered
bowel habits. Nor did he have any confusion or altered
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sleep pattern suggestive of hepatic encephalopathy. He
was previously well with no prior diagnosis of diabetes
mellitus, hypertension, or dyslipidemia. He was abstinent
from alcohol and he was not a tobacco smoker; he de-
nied any intravenous drug abuse, blood transfusions,
sexual promiscuity, or past history of hepatitis. There
was no family history of liver diseases or HCC.
On examination, he was not icteric or pale and there
was no bilateral leg edema or peripheral stigmata of
chronic liver cell disease. His cardiovascular system
examination was normal with a normal blood pressure.
His abdomen was distended with a palpable irregular
mass in the left lobe of his liver without a bruit. There
was no splenomegaly. A moderate amount of free fluid
was present. A neurological examination revealed no
signs of hepatic encephalopathy.
Initial basic investigations showed anemia and leukocytosis
with normal liver and renal biochemistry (Table 1). His
blood picture showed normochromic normocytic anemia
with mild to moderate rouleaux formation and mild neu-
trophilic leukocytosis. His inflammatory markers were
high with an erythrocyte sedimentation rate (ESR) of 125
in the first hour and a C-reactive protein (CRP) of
155 mg/L (<6). His urine full report was normal. His fast-
ing blood sugar (5.4 mmol/L) and lipid profile were nor-
mal. His lactate dehydrogenase (LDH) was 669 U/L (230
to 460) and amylase was 68 U/L (22 to 80).
Hepatitis B serology (hepatitis B surface antigen, hepa-
titis B surface antibody, and hepatitis B core antibody)
and hepatitis C serology (HCV antibody and hepatitis C
ribonucleic acid (RNA)) were negative as were human
immunodeficiency virus (HIV) serology and Venereal
Disease Research Laboratory (VDRL) test. Serum iron
studies were within normal range except for marginally
elevated serum ferritin (Table 1). His serum alpha-
fetoprotein was 12 μg/L. The result of an antinuclear
antibodies (ANA) test was negative and the ceruloplas-
min level in the serum was normal.
An ultrasound (USS) scan of his abdomen showed a
heterogeneous ill-defined area of 4.5 × 2.4 cm in the left
lobe of his liver with irregular margins. The rest of his
liver was normal with normal outline and uniform echo-
genicity without features of cirrhosis. His gall bladder
and bile ducts were normal. His spleen was mildly en-
larged (12.6 cm) and moderate ascites was present. A
portal vein Doppler showed normal flow pattern with no
evidence of portal vein thrombosis (portal vein diameter
0.98 cm and flow velocity 25 cm/second). There was no
para-aortic lymphadenopathy. His pancreas, kidneys,
and prostate were normal. A posteroanterior chest X-ray
(CXR-PA) showed elevation of his right hemidiaphragm
(Fig. 1).
Contrast-enhanced triple-phase computed tomog-
raphy (CT) showed a 7.5 × 6.5 cm lesion in the left
lobe of his liver which enhanced during the arterial
phase and showed a washout effect in the venous
phase (Fig. 2 shows liver lesion seen at 30 seconds
from contrast administration, delayed film; Fig. 3
shows liver lesion seen at 70 seconds, delayed film;
and Fig. 4 shows liver lesion seen in 5 minutes, de-
layed film). The right lobe of his liver was normal.
Intrahepatic and extrahepatic ducts were normal.
There were no para-aortic masses. Gross ascites was
evident (Fig. 5).
Table 1 Full blood count, liver function tests, renal function tests, and serum iron studies
Investigation Normal range Investigation Normal range
WBC = 11.15 × 103/μL 4–10 × 103/μL Neutrophil = 85.8% 50–70%
Lymphocyte = 8.4% 20–40% Eosinophil = 0.03% 0.5–05%
Hemoglobin = 9.7 g/dL 11–16 g/dL MCV = 92.4 fL 80–100 fL
MCH = 29.4 pg 27–34 pg MCHC 31.8 g/dL 32–36 g/dL
RDW-CV 0.119 0.110–0.160 Serum creatinine = 1.13 mg/dL 0.68–1.36 mg/dL
Serum sodium = 140 mmol/L 135–145 mmol/L Serum potassium = 4.7 mmol/L 3.5–5.1 mmol/L
Albumin = 37 g/L 36–50 g/L Globulin = 41.0 g/L 22–40 g/L
Alkaline phosphatase = 84 U/L 30–120 U/L GGT = 60 U/L (<55) <55 U/L
ALT = 37 U/L <50 U/L AST = 26 U/L <50 U/L
Total bilirubin = 6.7 μmol/L 5–21 μmol/L INR = 1.2 <1.4
Serum magnesium = 1.1 mmol/L 0.8–1.1 mmol/L Ionized calcium 1.27 mmol/L 1.0–1.3
Serum iron = 100.9 μg/dL 59–156 μg/dL TIBC = 349 291–430
Transferrin saturation = 30.8% 20–50% Ferritin = 388 ng/mL 28–365 ng/mL
ALT alanine aminotransferase AST aspartate aminotransferase GGT gamma-glutamyltransferase INR international normalized ratio MCH mean corpuscular
hemoglobin MCHC mean corpuscular hemoglobin concentration MCV mean corpuscular volume RDW random distribution of red cell width TIBC total iron-binding
capacity WBC White blood cell count.
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A diagnostic peritoneal tap revealed the ascitic fluid to
be slightly turbid and mildly blood stained. His ascitic
fluid albumin was 40 g/L (serum-to-ascites albumin gra-
dient = -03 g/L) and it contained 25 neutrophils/mm3,
160 lymphocytes/mm3, and 4000 red blood cells/mm3.
His glucose concentration was 4.0 mmol/L: random
blood sugar (RBS) 7.0 mmol/l. His adenosine deaminase
level was 29 U/L: tuberculosis (TB) 92 +/– 45, non-TB
12 +/– 11. An analysis of 200 mL of ascitic fluid for cy-
tology showed reactive mesothelial cells, histiocytes, and
lymphocytes. There was no evidence of atypical cells. A
Gram stain and bacterial cultures of ascitic fluid were
negative. Polymerase chain reaction (PCR) and culture
for TB were also negative.
Laparoscopic assessment revealed gross ascites, peri-
toneal deposits (Fig. 6), and omental deposits (Fig. 7)
with bowel adhesions. Ascitic fluid was drained and
cytological analysis of 500 mL was negative for malig-
nant cells. A liver lesion was seen at the left lobe of his
liver (Fig. 8) and biopsies were taken from the liver
lesion as well as omental and peritoneal deposits. TB
culture, TB PCR, and GeneXpert for Mycobacterium
tuberculosis in material retrieved from the liver lesion,
omental deposit, and peritoneal deposit were negative.
The biopsy from his liver showed nests and trabeculae
of cells with vesicular nuclei and prominent nucleoli
with sinusoidal pattern focally. Cytoplasmic bile stain-
ing and intranuclear inclusions were not seen. A biopsy
from his peritoneum and omentum showed nests of
similar cells infiltrating the desmoplastic stroma. These
findings supported a diagnosis of HCC which was con-
firmed by immunohistochemistry.
He refused any surgical or oncological interventions
and wished to be managed conservatively. He died
3 months later.
Discussion
There is much research on the etiology and management
of HCC in the cirrhotic liver. Data on the natural history
of HCC in non-cirrhotic patients are limited. A variety
of risk factors for the development of HCC have been
identified including cirrhosis of almost any cause, mostly
chronic viral hepatitis B or C, alcohol, nonalcoholic stea-
tohepatitis, and hemochromatosis. HCC usually develops
in the setting of chronic liver cirrhosis or inflammation
[5]; less than 20% of HCCs develop in the non-cirrhotic
liver [6]. As compared to HCC in a cirrhotic liver, HCC
in a non-cirrhotic liver has some peculiarities, such as:
lower male preponderance; bimodal age distribution;
lower prevalence of the three main risk factors of hepa-
titis B virus (HBV) infection, HCV infection, and alcohol
abuse; and increased prevalence of other etiologic factors
(exposure to genotoxic substances and sex hormones,
inherited diseases, and genetic mutations). Extrahepatic
extension is also more common in HCC in patients who
do not have cirrhosis [7, 8]. In the majority of patients
with HCC in a non-cirrhotic liver, the etiology can most
likely be related to metabolic syndrome [9]. It is also
very rare to develop HCC in a normal liver without
HBV and HCV infection.
One case report described a 36-year-old woman with
normal liver function and negative hepatitis virus
markers; abdominal USS, CT, and magnetic resonance
imaging (MRI) showed a tumor in segment 7 of her
liver. Upon aspiration biopsy of her liver, the histo-
pathological diagnosis was moderately differentiated
HCC [10]. Tanaka et al. [3] described a 39-year-old
woman with normal liver function and no evidence of
past and persistent HBV or HCV infection, whose ab-
dominal ultrasonography and abdominal CT scan dem-
onstrated a liver tumor of approximately 40 mm in
maximal diameter in the lateral segment. This tumor
was a moderately differentiated HCC. Tanaka et al.
concluded that it is very rare to develop HCC in a nor-
mal liver without HBV and HCV infection [3]. Liver
cancer is considered to be comparatively rare in young
patients. According to the 16th report of the national
follow-up study of primary liver cancer by Liver Cancer
Study Group of Japan, only 0.6% of all cases of HCC
occurred in patients younger than 35 years.
“Failure mode and effects analysis” [11] can be applied
as a clinical reasoning tool to our patient. HCC is the
potential failure. Effects of failure/main clinical features
were progressive abdominal distension, discomfort, loss
Fig. 1 A posteroanterior chest X-ray showed right-side
hemidiaphragm elevation
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of appetite, and loss of weight [11]. There was no bio-
chemical or radiological evidence of cirrhosis in our pa-
tient. We have excluded most of the risk factors for the
development of HCC. The results of both the hepatitis B
surface antigen and hepatitis B surface antibody tests
were negative which excluded acute or chronic hepatitis
B infection and previous exposure. This was also con-
firmed by negative hepatitis B core antibodies (IgM and
IgG). Negative hepatitis C serology (anti-HCV antibody
and hepatitis C RNA) excluded hepatitis C infection. He
was abstinent from alcohol and did not have diabetes
mellitus, hypertension, obesity, or hypertriglyceridemia
suggesting metabolic syndrome, which is associated with
nonalcoholic steatohepatitis. He did not have a history
of exposure to aflatoxin or other environmental toxins,
which can contribute to the pathogenesis of HCC. Nor-
mal iron studies and ceruloplasmin levels excluded
hemochromatosis and Wilson disease. He did not have
any features of autoimmune hepatitis and an ANA test
was negative. His alpha-1 antitrypsin level was not tested
due to financial constraints. However, he had no features
of emphysema or panniculitis. Therefore we conclude
that this is a rare case of a 41-year-old patient with HCC
in a non-cirrhotic liver with negative hepatitis ser-
ology. Ascitic fluid was an exudate (serum-to-ascites
albumin gradient was less than 11 g/L) and was
lymphocyte predominant. His adenosine deaminase
level, a purine-degrading enzyme needed for matur-
ation and differentiation of lymphoid cells, can be used
to detect tuberculous peritonitis and in this case was
not supportive of TB peritonitis. TB PCR and TB cul-
ture were also negative. We sent approximately
700 mL of ascitic fluid for cytological analysis as the
sensitivity increases up to 80 to 90% with increasing
volume of ascitic fluid. However, atypical cells were
not found.
HCC is highly aggressive and often detected at a late
stage. As in our patient, the symptoms are not specific
in the early stages of the disease. More than 60% of pa-
tients are diagnosed at a late stage of disease after
Fig. 2 Liver lesion seen in 30 seconds, delayed film. Contrast-enhanced computed tomography of the abdomen
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metastasis has occurred [12]. Since early stage disease
has a relatively good prognosis, it is important to iden-
tify the lesion early. Alpha fetoprotein is the most com-
monly used biomarker for HCC detection and some
other new biomarkers such as glypican-3, osteopontin,
Golgi protein 73, nucleic acids including microRNAs,
Dickkopf-1 (DKK1), and midkine (MDK) will become
clinically available in the near future [13, 14]. Chiou and
Lee [15] identified two mediators of inflammation, S100
calcium-binding protein A9 (S100A9) and granulin
Fig. 4 Liver lesion seen in 5 minutes, delayed film. Contrast-enhanced computed tomography of the abdomen
Fig. 3 Liver lesion seen in 70 seconds, delayed film. Contrast-enhanced computed tomography of the abdomen
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protein markers, as HCC-associated cancer-specific bio-
markers. They belong to the cytoplasmic alarmin family
of the host innate immune system [15]. Even though
these biomarkers were not available to us, in future they
will be useful to identify HCC at an early stage.
The most frequent locations for metastasis of HCC
were lungs, portal vein, bones, and regional lymph nodes
[16–18]. Although the risk of metastasis in a ruptured
HCC is high [4], intraperitoneal metastasis of a non-
ruptured HCC is rare with an incidence of 2 to 6% de-
tected during autopsy or laparoscopy [19]. Peritoneal
metastases can occur synchronously or metachronously
[20]. Our patient did not have a ruptured HCC. Sudden
onset epigastric or right hypochondrial pain was the
Fig. 5 Gross ascites. Contrast-enhanced computed tomography of the abdomen
Fig. 6 Peritoneal deposits visualized at laparoscopy Fig. 7 Omental deposits visualized at laparoscopy
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main reported complaint of patients with a ruptured
HCC [21, 22]. Physical signs of hemodynamic instability,
reduced hemoglobin level, and a raised aspartate amino-
transferase level were more frequently found in patients
with ruptured HCC than in those with non-ruptured tu-
mors [22]. Peripheral location, protruding contour, dis-
continuity of hepatic surface, surrounding hematoma,
and the “enucleation sign” are helpful signs for the diag-
nosis of a ruptured HCC in CT [23]. None of these were
present in our patient.
Intraperitoneal seeding from a hepatoma can present
as intraperitoneal masses, peritoneal thickening, and as-
cites. The main vascular feeders to intraperitoneal
masses were omental branches of the gastroduodenal
artery and/or the superior mesenteric artery [24]. The
radiological manifestations of intraperitoneal metastasis
from a HCC are single or multiple discrete hypervascu-
lar masses in the omentum. On angiography, the omen-
tal masses will show hypervascularity and are supplied
by the omental branches of the superior mesenteric and
inferior mesenteric arteries with prominent draining
veins [25].
Surgery appears to be the optimal approach of man-
aging extrahepatic metastasis of HCC localized to the
peritoneum after considering the performance status,
liver function, and tumor biology. The prognosis after
cytoreductive surgery is likely to be related to the sever-
ity of chronic liver disease, the extent of peritoneal
tumor involvement, and the response to surgery [26].
Resection of peritoneal metastases should be consid-
ered in patients whose primary liver neoplasm is under
control and who have no metastases in other organs
[20, 27]. Unfortunately, our patient decided to be man-
aged conservatively without any interventions.
Conclusions
HCC usually develops in the setting of chronic liver cir-
rhosis or inflammation associated with chronic hepatitis
B and hepatitis C. Here we report a rare case of a large
HCC in the non-cirrhotic liver of a 41-year-old man
without chronic hepatitis presenting with peritoneal and
omental metastasis. As compared to HCC in a cirrhotic
liver, these tumors have some differences in epidemi-
ology and etiology. Intraperitoneal metastasis of a non-
ruptured HCC is very rare and cytoreductive surgery
should be considered in those patients after careful
assessment.
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